The impact of cohorts and studies in dementia research
Access to data from cohorts and studies in dementia research is vital for diagnosing the disease earlier. DPUK is making access easier, by bringing together data from 40 cohorts and working with industry.
The Impact of DPUK
DPUK set out to transform the way dementia research is done by harnesses the unique power of cohorts and studies in dementia research. DPUK's experimental medicine studies, which are small-scale studies in humans, learn from cohorts and then add further insights to dementia research.
Enhancing cohorts and studies in dementia research requires investment in technology, and collaboration with industry. To speed up this development DPUK's imaging and stem cell technology networks bring together research institution and industry resources. This pooled expertise generates bigger and braver ideas- giving hope that research will turn discovery science into life-changing medicines.
Cohorts in dementia research
Cohorts are long-term studies of health. They are critical to researchers' understanding of how and why disease develops and how we treat it. Over 3.5% of the UK population is a part of a cohort study. This offers a wealth of data to shape dementia research.
The Deep and Frequent Phenotyping study (DFP)
One of the big challenges facing dementia researchers is how to diagnose and track Alzheimer's disease in its earliest stages – before symptoms show. The DFP study will help scientists identify early warning signs of this condition, and to track responses to treatments.
Stem cells network and studies
© Anna Lukala
Imaging network and studies
Experimental medicine studies
Publications and protocols
DPUK publishes experimental medicine, epidemiology, imaging and stem cell technology.
DPUK cohorts in the Data Portal
Find out how to access over 40 different cohorts for dementia research and how DPUK can support you.
New spaces for new ideas
By providing the opportunity for academic and industry scientists to get to together, DPUK's research communities have broken down traditional barriers and nurtured innovative collaborations.
Repurposing the drug libraries
Using the patient-specific cell models derived from DPUK cohorts, a joint research team is investigating the behaviour of drugs developed by AstraZeneca (AZ) to identify new avenues for treatments.
Joining up the dots
DPUK investment has enabled scientists to study the development of brain disease using a type of stem cell derived from the blood samples of cohort study participants.